The JAK/STAT signaling pathway mediates a wide range of biological processes, and JAK inhibitors have been approved for use in myelofibrosis; subsequently, the role of JAK/STAT in fibrosis of other organs has come to the attention of researchers [35]. Here, SOAT1 is linked to myelofibrosis.